A brain-computer interface that allowed a man, 45, with ALS to communicate using recordings of his own voice has won a $7,500 ...

Treatment with regulatory T-cells, known as Tregs, was well tolerated and seemed to reduce disease activity in a small ...

Columnist Dagmar Munn shares the strategy that helps her get unstuck when she's not feeling motivated. Time is precious with ...

The FDA cleared the launch of a Phase 1 clinical trial to test cell therapy XS-228 in people with amyotrophic lateral ...

While life with ALS brings continued disease progression, columnist Kristin Neva is encouraged by signs of renewal outdoors.

Columnist Juliet Taylor explains how her goals and priorities dramatically shifted while living with her late husband's ALS.

AMX0114 is an antisense oligonucleotide made to prevent or slow the degeneration of axons, which is a key driver of ALS ...

A three-drug combination worked better than any of them alone in treating ALS caused by mutations in the SOD1 gene, per a new ...

The first ALS patient has been enrolled in an NIH-funded expanded access program trial evaluating MN-166 (ibudilast).

Brainstorm Cell Therapeutics is seeking FDA clearances to launch a Phase 3b clinical trial to test its NurOwn stem cell ...

Neurosense Therapeutics’ PrimeC significantly reduces blood levels of miRNAs linked to amyotrophic lateral sclerosis, trial ...

Columnist Dagmar Munn explains how the use of a shoehorn not only helps her put on shoes, but also allows for some gentle stretching.